Clinical Trial Detail

NCT ID NCT02435849
Title Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL (ELIANA)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

childhood B-cell acute lymphoblastic leukemia

Therapies

Tisagenlecleucel

Age Groups: adult child

No variant requirements are available.